CDER Director George Tidmarsh said on two separate events last week that he thought advisory committee meetings for specific ...

I don’t think they’re needed,” said George Tidmarsh, head of the FDA’s Center for Drug Evaluation and Research.

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

The FDA is moving to scale back its long-standing use of expert panels to review drug applications, KFF Health News reported Sept. 12. George Tidmarsh, MD, PhD, director of the FDA’s Center for Drug ...

He relayed the message Tuesday at a meeting of health care product makers and Wednesday to an FDA advocacy group. In addition ...

The FDA is planning to call on the health-care industry and consumers to provide information on the benefits of switching a prescription drug to over-the-counter, the agency’s drug chief said Tuesday.

The FDA reinstated normal regulations on compounded GLP-1s after a temporary relaxation during a shortage, emphasizing safety ...

The Food and Drug Administration has created a new “green list” import alert to stop potentially unsafe GLP-1 drug ingredients, including semaglutide and tirzepatide, from entering the U.S. from ...

The Food and Drug Administration is cracking down on ingredients from potentially from unverified foreign sources and that ...